

2025 ASCO[®] ANNUAL MEETING



Dra. Beatriz García Paredes

Servicio de Oncología. Hospital Clínico San Carlos de Madrid. Instituto de Investigación
Hospital Clínico San Carlos (IdISSC). Universidad Complutense, Madrid

TITULARES EN CÁNCER DE PÁNCREAS

Resumen en vídeo

Resumen en texto

CASSANDRA

Results of a randomized phase III trial of pre-operative chemotherapy with
mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma

Ver Abstract

PANOVA-3

PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and
nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC)

Ver Abstract



GRUPO DE TRATAMIENTO
DE LOS TUMORES DIGESTIVOS

2025 ASCO[®] ANNUAL MEETING



Dra. Beatriz García Paredes

Servicio de Oncología. Hospital Clínico San Carlos de Madrid. Instituto de Investigación
Hospital Clínico San Carlos (IdISSC). Universidad Complutense, Madrid

TITULARES EN CÁNCER DE PÁNCREAS

Resumen en vídeo

Resumen en texto

ABSTRACT 4006

Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC)

Ver Abstract

TEDOPAM GERCOR D17-01 PRODIGE 63

4Maintenance with OSE2101 plus FOLFIRI vs FOLFIRI alone after FOLFIRINOX (FFX) induction in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): Primary endpoint results of a randomized TEDOPAM GERCOR D17-01 PRODIGE 63 trial

Ver Abstract



GRUPO DE TRATAMIENTO
DE LOS TUMORES DIGESTIVOS